C. Grohe

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175].

INTRODUCTION In ADAURA, adjuvant osimertinib improved DFS and OS versus placebo in resected EGFR-mutated stage IB-IIIA NSCLC. We report a post hoc exploratory analysis of long-term OS post-adjuvant treatment completion. METHODS Patients (N = 682) were randomized to osimertinib or placebo until recurrence, treatment c...

LUCAID: Agentic Multimodal AI for Lung Cancer Precision Pathology

LUCAID is an agentic AI system for precision lung cancer pathology that combines diagnostic reasoning with nine modules that cover the full routine workflow, from quality control, tumor detection and segmentation, histological subtyping, tumor microenvironment profiling, tumor cellularity quantification, and predictive...